Skip to main content
SLS
NASDAQ Life Sciences

SELLAS Triples as Cancer Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$20.45
Mkt Cap
$1.523B
52W Low
$1.39
52W High
$24.89
52W Position info
1371% above low
Off High info
18% below high
Rel. Volume info
9.4× avg
Market data snapshot near publication time

SLS has more than doubled off its 52-week low of $1.39 on elevated volume (9.4× avg).

Summary

The pivotal Phase 3 REGAL trial of galinpepimut-S met its primary overall survival endpoint in second-remission AML, cutting death risk 41% (hazard ratio 0.59, p=0.035). Median overall survival was 24.0 months on GPS versus 14.7 months for best available treatment, with no new safety signals. The stock tripled to a 52-week high of $21.14 on 57.6 million shares versus a 6.9 million average. This follows the October 28 announcement that the trial hit its pre-specified 80th death event, which triggered this analysis. The company now plans to meet the FDA on an accelerated filing strategy and submit a BLA in the first half of 2027.

At the time of this announcement, SLS was trading at $20.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $24.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

SLS - Latest Insights

SLS
Nov 17, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $8.00
Real-time Price: $20.55 info
Change: +$12.55 (+157%) info
Market Cap: $1.523B info
SLS
Nov 12, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.01
Real-time Price: $20.55 info
Change: +$12.55 (+157%) info
Market Cap: $1.523B info
SLS
Oct 28, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.75
Real-time Price: $20.55 info
Change: +$7.80 (+61%) info
Market Cap: $1.523B info
SLS
Oct 01, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $12.36
Real-time Price: $20.55 info
Change: +$8.19 (+66%) info
Market Cap: $1.523B info
SLS
Aug 11, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $20.55 info
Change: +$9.58 (+87%) info
Market Cap: $1.523B info